SCHEMBL4239043

SCHEMBL4239043

Cc1nn(-c2ccc(Br)cc2)c(C)c1C=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
HTT P42858 2/20 0.46
LMNA P02545 2/20 0.46
ALOX15 P16050 1/20 0.45
ALDH1A1 P00352 4/20 0.43
POLB P06746 3/20 0.43
KDM4E B2RXH2 2/20 0.43
OPRM1 P35372 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
MAPT P10636 2/20 0.41
APEX1 P27695 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
KDM4C Q9H3R0 1/20 0.40
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PTGS2 P35354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27875396 0.86 ALDH1A1 (0.49) NPC1RAB9AHTTLMNAALOX15
SCHEMBL15332484 0.84 MAPT (0.53) NPC1RAB9AHTTLMNAALDH1A1
SCHEMBL13739457 0.83 MAPT (0.51) NPC1RAB9AHTTLMNAALOX15
SCHEMBL1779819 0.83 HTT (0.64) NPC1RAB9AHTTLMNAALOX15
SCHEMBL3321050 0.81 HTT (0.47) NPC1RAB9AHTTLMNAALOX15
SCHEMBL5904596 0.80 BRAF (0.43) HTTLMNAALOX15POLBKDM4E
SCHEMBL4241325 0.80 AR (0.53) HTTLMNAALOX15POLBKDM4E
SCHEMBL4232107 0.79 HTT (0.40) HTTLMNAALOX15ALDH1A1POLB
SCHEMBL28807415 0.79 CYP1A2 (0.55) NPC1RAB9AHTTLMNAALOX15
SCHEMBL24185323 0.77 NPC1 (0.56) NPC1RAB9ALMNAALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102731477-B Pyrazoloquinoline compound and derivatives thereof, as well as preparation method and application thereof UNIV HENAN 2014-02-05 CN disclosed
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
WO-2009119880-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270361-A1 Substituted pyrazole derivatives and use thereof CBR3, CBR1, NOX5 NPC1 1077/4885RAB9A 3098/4885HTT 3308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.